Bank of America Corp DE Purchases 6,113 Shares of Bioventus Inc. (NYSE:BVS)

Bank of America Corp DE lifted its position in Bioventus Inc. (NYSE:BVS) by 3.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 174,554 shares of the company’s stock after acquiring an additional 6,113 shares during the quarter. Bank of America Corp DE owned approximately 0.22% of Bioventus worth $1,833,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its stake in shares of Bioventus by 11.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 435,344 shares of the company’s stock worth $4,571,000 after acquiring an additional 45,182 shares in the last quarter. Principal Financial Group Inc. grew its stake in shares of Bioventus by 9.4% in the 4th quarter. Principal Financial Group Inc. now owns 19,228 shares of the company’s stock worth $202,000 after acquiring an additional 1,652 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Bioventus by 18.7% in the 4th quarter. Vanguard Group Inc. now owns 2,462,081 shares of the company’s stock worth $25,852,000 after acquiring an additional 388,174 shares in the last quarter. Barclays PLC boosted its holdings in shares of Bioventus by 31.0% in the 4th quarter. Barclays PLC now owns 66,337 shares of the company’s stock worth $696,000 after buying an additional 15,683 shares during the last quarter. Finally, Spire Wealth Management purchased a new position in shares of Bioventus in the 4th quarter worth about $402,000. Institutional investors own 62.94% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on BVS shares. Craig Hallum set a $15.00 price target on shares of Bioventus and gave the stock a “buy” rating in a report on Wednesday, May 7th. Canaccord Genuity Group reissued a “buy” rating and issued a $15.00 price target on shares of Bioventus in a report on Monday, March 17th.

Insider Buying and Selling at Bioventus

In other Bioventus news, CFO Mark Leonard Singleton sold 5,479 shares of the company’s stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $9.79, for a total transaction of $53,639.41. Following the sale, the chief financial officer now directly owns 131,963 shares of the company’s stock, valued at $1,291,917.77. This represents a 3.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 13,330 shares of company stock valued at $115,291 over the last three months. 32.90% of the stock is currently owned by insiders.

Bioventus Price Performance

Shares of NYSE:BVS opened at $6.66 on Wednesday. The company’s 50-day moving average is $7.37 and its 200 day moving average is $9.39. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. The company has a market capitalization of $547.08 million, a P/E ratio of -10.92 and a beta of 0.95. Bioventus Inc. has a fifty-two week low of $5.28 and a fifty-two week high of $14.38.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.